Kiniksa Pharmaceuticals International (KNSA) Competitors

$49.27 +0.57 (+1.17%)

Closing price 04:00 PM Eastern

Extended Trading

$49.31 +0.04 (+0.08%)

As of 04:47 PM Eastern

KNSA vs. ASND, BBIO, ELAN, AXSM, and SMMT

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? MarketBeat compares Kiniksa Pharmaceuticals International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiniksa Pharmaceuticals International include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 3 mentions for Kiniksa Pharmaceuticals International. Ascendis Pharma A/S's average media sentiment score of 1.32 beat Kiniksa Pharmaceuticals International's score of 1.14 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, suggesting a potential upside of 23.52%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 40.80%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ascendis Pharma A/S has a net margin of 57.87% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74
Ascendis Pharma A/S	$814.57M	16.07	-$258M	$8.67	24.20

Summary

Ascendis Pharma A/S beats Kiniksa Pharmaceuticals International on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its share price is 88% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74
BridgeBio Pharma	$502.08M	26.29	-$724.93M	-$3.74	N/A

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, suggesting a potential upside of 23.52%. BridgeBio Pharma has a consensus price target of $89.59, suggesting a potential upside of 32.92%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, BridgeBio Pharma had 11 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for BridgeBio Pharma and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat BridgeBio Pharma's score of 0.93 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to BridgeBio Pharma's net margin of -124.42%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 9 of the 15 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Elanco Animal Health presently has a consensus target price of $28.20, indicating a potential upside of 22.90%. Kiniksa Pharmaceuticals International has a consensus target price of $60.86, indicating a potential upside of 23.52%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

In the previous week, Elanco Animal Health had 10 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for Elanco Animal Health and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat Elanco Animal Health's score of 0.90 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Elanco Animal Health's net margin of -4.95%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Kiniksa Pharmaceuticals International has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.43	-$232M	-$0.50	N/A
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74

Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

Summary

Kiniksa Pharmaceuticals International beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Axsome Therapeutics had 12 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 15 mentions for Axsome Therapeutics and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat Axsome Therapeutics' score of 0.42 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Axsome Therapeutics' net margin of -26.59%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Kiniksa Pharmaceuticals International has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74
Axsome Therapeutics	$638.50M	19.85	-$183.17M	-$3.73	N/A

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kiniksa Pharmaceuticals International presently has a consensus price target of $60.86, indicating a potential upside of 23.52%. Axsome Therapeutics has a consensus price target of $251.26, indicating a potential upside of 2.00%. Given Kiniksa Pharmaceuticals International's higher possible upside, research analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Kiniksa Pharmaceuticals International beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Summit Therapeutics had 15 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 18 mentions for Summit Therapeutics and 3 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.14 beat Summit Therapeutics' score of 0.60 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.59	$59.01M	$0.90	54.74
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Summit Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
Summit Therapeutics	N/A	-291.24%	-243.07%

Kiniksa Pharmaceuticals International has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Kiniksa Pharmaceuticals International currently has a consensus target price of $60.86, indicating a potential upside of 23.52%. Summit Therapeutics has a consensus target price of $26.05, indicating a potential upside of 99.65%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Kiniksa Pharmaceuticals International beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.75B	$3.28B	$6.41B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	54.11	18.99	24.46	23.62
Price / Sales	5.59	290.48	500.50	105.26
Price / Cash	61.35	118.24	42.36	56.09
Price / Book	6.62	8.00	10.43	6.70
Net Income	$59.01M	$23.89M	$3.56B	$337.26M
7 Day Performance	2.97%	-3.49%	-1.39%	-1.41%
1 Month Performance	-15.92%	1.03%	0.86%	1.15%
1 Year Performance	65.50%	34.39%	19.42%	22.61%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	4.4371 of 5 stars	$49.27 +1.2%	$60.86 +23.5%	+60.6%	$3.75B	$677.56M	54.11	220	Positive News Analyst Upgrade
ASND Ascendis Pharma A/S	4.6894 of 5 stars	$218.84 +0.9%	$295.39 +35.0%	+23.1%	$13.65B	$814.57M	25.24	1,189	Positive News Analyst Forecast
BBIO BridgeBio Pharma	3.5538 of 5 stars	$67.33 +2.8%	$89.59 +33.1%	+73.4%	$13.19B	$502.08M	N/A	400	Insider Trade
ELAN Elanco Animal Health	3.8744 of 5 stars	$24.69 +0.5%	$28.20 +14.2%	+75.6%	$12.33B	$4.72B	N/A	9,400
AXSM Axsome Therapeutics	1.8197 of 5 stars	$231.48 -0.9%	$251.26 +8.5%	+123.6%	$11.91B	$638.50M	N/A	380	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Summary

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Which has more volatility and risk, KNSA or ASND?

Do insiders & institutionals have more ownership in KNSA or ASND?

Does the media refer more to KNSA or ASND?

Do analysts recommend KNSA or ASND?

Is KNSA or ASND more profitable?

Which has stronger earnings and valuation, KNSA or ASND?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Which has more risk and volatility, KNSA or BBIO?

Which has stronger valuation & earnings, KNSA or BBIO?

Do analysts recommend KNSA or BBIO?

Does the media favor KNSA or BBIO?

Do insiders and institutionals hold more shares of KNSA or BBIO?

Is KNSA or BBIO more profitable?

Summary

How does Kiniksa Pharmaceuticals International compare to Elanco Animal Health?

Do institutionals & insiders believe in ELAN or KNSA?

Do analysts prefer ELAN or KNSA?

Does the media prefer ELAN or KNSA?

Is ELAN or KNSA more profitable?

Which has preferable valuation and earnings, ELAN or KNSA?

Which has more volatility and risk, ELAN or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to Axsome Therapeutics?

Does the media favor KNSA or AXSM?

Is KNSA or AXSM more profitable?

Which has more risk & volatility, KNSA or AXSM?

Which has higher valuation and earnings, KNSA or AXSM?

Do institutionals and insiders hold more shares of KNSA or AXSM?

Do analysts prefer KNSA or AXSM?

Summary

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Does the media refer more to KNSA or SMMT?

Do institutionals & insiders hold more shares of KNSA or SMMT?

Which has preferable earnings & valuation, KNSA or SMMT?

Is KNSA or SMMT more profitable?

Which has more risk and volatility, KNSA or SMMT?

Do analysts prefer KNSA or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools